GSK Opposes Cert, Assails Government’s Brief Over Generic Drug Label Carve-Outs
WASHINGTON, D.C. — In a supplemental brief filed in response to the U.S. government’s amicus curiae brief supporting a generic drugmaker’s petition for certiorari, GlaxoSmithKline LLC (GSK) accuses the government of...To view the full article, register now.
Already a subscriber? Click here to view full article